Association of IDH1 Mutation Detected in Circulating-free DNA With Survival Outcome in Patients Affected by Glioma

Association of IDH1 Mutation Detected in Circulating-free DNA With Survival Outcome in Patients Affected by Glioma

Saved in:

Bibliographic Details
Main Authors:	M. Ruglioni, S. Crucitta, F. Pasqualetti, A. Gonnelli, G. Luculli, M. Cantarella, V. Ortenzi, C. Scatena, F. Paiar, A. Naccarato, R. Danesi, M. Del Re
Format:	Article
Language:	English
Published:	Elsevier 2023-11-01
Series:	The Journal of Liquid Biopsy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2950195423000528
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications
by: Kristian A. Choate, et al.
Published: (2024-10-01)

IDH mutation, glioma immunogenicity, and therapeutic challenge of primary mismatch repair deficient IDH‐mutant astrocytoma PMMRDIA: a systematic review
by: Olfat Ahmad, et al.
Published: (2024-12-01)

Detection of IDH mutation in glioma by desorption electrospray ionization (DESI) tandem mass spectrometry
by: Mahdiyeh Shahi, et al.
Published: (2024-11-01)

The relationship between IDH, P53 mutations, MGMT methylation with characteristics in high grade glioma patients
by: Duc Anh Tran, et al.
Published: (2022-07-01)

Association of IDH1 Mutation and MGMT Promoter Methylation with Clinicopathological Parameters in an Ethnically Diverse Population of Adults with Gliomas in England
by: Hiba A. Wanis, et al.
Published: (2024-11-01)

Clinical characteristics of EGFR-ctDNA shedders in EGFR-mutant NSCLC patients
by: Martina Ruglioni, et al.
Published: (2025-02-01)

Spinal IDH-wildtype glioma: a single center experience of rare disease
by: H. Gull, et al.
Published: (2024-01-01)

IDH-mutant gliomas in children and adolescents - from biology to clinical trials
by: Louise Evans, et al.
Published: (2025-01-01)

Multipool-CEST and CEST-based pH assessment as predictive tools for glioma grading, IDH mutation, 1p/19q codeletion, and MGMT promoter methylation in gliomas
by: Xinli Zhang, et al.
Published: (2024-12-01)

The Relationship Between IDH1 Mutation Status and Metabolic Imaging in Nonenhancing Supratentorial Diffuse Gliomas: A C-MET PET Study
by: Nijiati Kudulaiti MD, et al.
Published: (2019-12-01)

Efficacy and safety of IDH inhibitors in IDH-mutated cancers: a systematic review and meta-analysis of 4 randomized controlled trials
by: Zelin Cai, et al.
Published: (2024-11-01)

IDH-mutant glioma risk stratification via whole slide images: Identifying pathological feature associations
by: Xiaotao Wang, et al.
Published: (2025-01-01)

Multidisciplinary quantitative and qualitative assessment of IDH-mutant gliomas with full diagnostic deep learning image reconstruction
by: Christer Ruff, et al.
Published: (2024-12-01)

Gliomas Difusos do Adulto: Prevalência da Mutação IDH1 em um Hospital Universitário
by: Vitor Bonk Rizzo, et al.
Published: (2025-01-01)

VASARI 2.0: a new updated MRI VASARI lexicon to predict grading and IDH status in brain glioma
by: Alberto Negro, et al.
Published: (2024-12-01)

Radiomic study on preoperative multi‐modal magnetic resonance images identifies IDH‐mutant TERT promoter‐mutant gliomas
by: Haoyu Wang, et al.
Published: (2023-02-01)

Completely non-invasive prediction of IDH mutation status based on preoperative native CT images
by: Manfred Musigmann, et al.
Published: (2024-11-01)

Bortezomib and low dose venetoclax therapy for relapsed/refractory B-cell acute lymphoblastic leukemia with IDH1 mutation
by: Pronamee Borah, et al.
Published: (2024-12-01)

Genetic predisposition to altered blood cell homeostasis is associated with glioma risk and survival
by: Linda Kachuri, et al.
Published: (2025-01-01)

Predicting survival in malignant glioma using artificial intelligence
by: Wireko Andrew Awuah, et al.
Published: (2025-01-01)

Comparative analysis of the profile of circulating microRNAs in the blood plasma of patients with gliomas
by: D. Yu. Gvaldin, et al.
Published: (2024-06-01)

Preoperative prediction of IDH genotypes and prognosis in adult-type diffuse gliomas: intratumor heterogeneity habitat analysis using dynamic contrast-enhanced MRI and diffusion-weighted imaging
by: Xingrui Wang, et al.
Published: (2025-02-01)

Effects of Levetiracetam and Lacosamide on survival and seizure control in IDH-wild type glioblastoma during temozolomide plus radiation adjuvant therapy
by: Andrea Bianconi, et al.
Published: (2024-01-01)

BRAF inhibitor monotherapy in BRAFV600E-mutated pediatric low-grade glioma: a single center’s experience
by: S. S. McThenia, et al.
Published: (2025-01-01)

Circulating Tumor Cells as a Non-invasive Glioblastoma Diagnostic and Prognostic Tool
by: F. Lessi, et al.
Published: (2023-11-01)

IDH Mutant Cholangiocarcinoma: Pathogenesis, Management, and Future Therapies
by: Alexander Bray, et al.
Published: (2025-01-01)

Venetoclax and Azacitidine Combination is an Effective Salvage Regimen for Fit Patients with IDH-2-mutated Acute Myeloid Leukemia Refractory to Conventional Induction Chemotherapy
by: Musa Fares Alzahrani
Published: (2024-12-01)

Ovarian juvenile granulosa cell tumor accompanying Oliver's disease with IDH1 gene somatic mutation: A case study and literature review
by: Zeyuan Yu, et al.
Published: (2025-02-01)

Circulating Tumor DNA Monitoring in Advanced Mutated Melanoma Treated With Immune Checkpoint Inhibitors: A Pilot Study
by: G. Monica, et al.
Published: (2023-11-01)

Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS (LUMOS-2): study protocol for a phase 2, prospective, multicentre, open-label, multiarm, biomarker-directed, signal-seeking, umbrella, clinical trial for recurrent IDH mutant, grade 2/3 glioma
by: Marshall Pitz, et al.
Published: (2025-02-01)

Letter to the editor “Effects of levetiracetam and lacosamide on survival and seizure control in IDH-wild type glioblastoma during temozolomide plus radiation adjuvant therapy”
by: Niher Tabassum Snigdha
Published: (2024-01-01)

Mutational Prognosis of Survival by Liquid Biopsy in Advanced EGFRm NSCLC
by: M. Galvez-Nino, et al.
Published: (2023-11-01)

Discontiguous recurrences of IDH-wildtype glioblastoma share a common origin with the initial tumor and are frequently hypermutated
by: Malcolm F. McDonald, et al.
Published: (2025-01-01)

Ibrutinib disrupts blood-tumor barrier integrity and prolongs survival in rodent glioma model
by: Sanghee Lim, et al.
Published: (2024-04-01)

TGF-β mRNA Expression Levels in Extracellular Vesicles Are Associated With Immunotherapy Response in Metastatic Melanoma Patients
by: S. Crucitta, et al.
Published: (2023-11-01)

How to survive the mutational meltdown: lessons from plant RNA viruses
by: Lafforgue, Guillaume, et al.
Published: (2024-02-01)

The relationship between TP53 Gene Mutation with treatment results in High-Grade Gliomas
by: Bac Thanh Nguyen, et al.
Published: (2024-05-01)

Unravelling mutational signatures with plasma circulating tumour DNA
by: Sebastian Hollizeck, et al.
Published: (2024-11-01)

Valproic acid targets IDH1 mutants through alteration of lipid metabolism
by: Lubayna S. Elahi, et al.
Published: (2024-08-01)

Effect of Electronic Moxibustion in Patients with IDH: A Randomized Crossover Pilot Study
by: Liu TJ, et al.
Published: (2024-12-01)